Summary of the technology
Companion diagnostic for cutaneous and uveal melanoma. Our combination drug therapy for metastatic melanoma offers an alternative treatment for patients that do not have the BRAF V600 mutation or for patients resistant to Vemurafenib. Additionally, our technology can be used as a prognostic test to predict the risk of metastasis in uveal and cutaneous melanoma.
Description of the technology
Metastases are the leading cause of death in cutaneous and uveal melanoma patients in whom conventional therapies fail. Specific plasma biomarkers to identify patients at high risk of recurrence and help health care professionals take therapeutic decisions, are urgently needed. New therapeutic options are also necessary.
1. A group of exosomal miRNAs, which are present in blood and lymphatic torrent of melanoma patients, have been identified as good predictor markers of metastasis. Clinicians of HUB, who have collected blood and plasma samples of patients at different stages of their cancer progression, are now validating these markers.
2. Through an in vitro screening, the research group has selected two proteins as potential inhibitors of tumor progression. These proteins target several signaling pathways related to metastasis and also inhibit the survival of cancer Stem Cells.
The invention could be used as a companion diagnostic to help healthcare professionals determine the best therapeutic option for melanoma patients. Doctors could know in advance which patients would probably develop metastasis. As well as, they would have an alternative treatment for those patients that do not have the BRAF V600 mutation or for patients resistant to Vemurafenib.
Technology Transfer Office
Additional information (attached documents)